Brent Holt, MD
Family Medicine · Pocahontas, ARNPI 1053300558
Payments from drug & device makers
Across 347 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tosoh Bioscience, Inc.$1K
- Novo Nordisk$1K
- Amgen$803
- AstraZeneca$577
- AbbVie$526
- Astellas Pharma US Inc$314
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,00775%
- Education$1773%
- Gifts$1,45122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tosoh Bioscience, Inc. | 1 | $1,451 |
| Novo Nordisk | 72 | $1,083 |
| Amgen | 68 | $803 |
| AstraZeneca | 24 | $577 |
| AbbVie(2 entities) | 38 | $526 |
| Astellas Pharma US Inc | 19 | $314 |
| Novartis | 19 | $251 |
| Merck | 17 | $166 |
| Pfizer | 11 | $164 |
| GSK | 9 | $149 |
| Bayer | 7 | $147 |
| Lilly USA, LLC | 10 | $144 |
| Johnson & Johnson | 9 | $124 |
| Boehringer Ingelheim | 4 | $118 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| E.r. Squibb & Sons, L.L.C. | 5 | $58 |
| Sumitomo Pharma America, Inc. | 3 | $57 |
| Corcept Therapeutics | 2 | $51 |
| Amarin Pharma, Inc. | 3 | $51 |
| Sanofi-aventis U.S. LLC | 4 | $48 |
| Exact Sciences | 3 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 3 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $27 |
| Averitas Pharma Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Dexcom, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TSH, ST AIA-PACK$1,451
- PA, ST AIA-PACK$1,451
- BREZTRI$111
- FARXIGA$111
- AIRSUPRA$111
How this compares
$6,634 in reported general payments places this provider in the 85th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 229 | $134,917 |
| EliquisApixaban | 131 | $86,855 |
| OzempicSemaglutide | 84 | $78,467 |
| Tresiba Flextouch U-200Insulin Degludec | 46 | $66,995 |
| FarxigaDapagliflozin Propanediol | 121 | $62,837 |
| Tresiba Flextouch U-100Insulin Degludec | 107 | $59,356 |
| JanuviaSitagliptin Phosphate | 88 | $50,930 |
| MounjaroTirzepatide | 46 | $46,454 |
| TrulicityDulaglutide | 39 | $41,132 |
| MyrbetriqMirabegron | 95 | $35,673 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $34,817 |
| XareltoRivaroxaban | 60 | $34,650 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $30,479 |
| LinzessLinaclotide | 56 | $29,434 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 63 | $20,166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy, Combivent Respimat | $118 | $177,165288 claims |
| PfizerEliquis, Nurtec Odt | $164 | $102,708146 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $577 | $101,362175 claims |
| Lilly USA, LLCMounjaro, Trulicity | $144 | $87,58785 claims |
| Novo NordiskOzempic | $1,083 | $78,46784 claims |
| MerckJanuvia, Janumet | $166 | $57,495101 claims |
| AbbVieLinzess, Vraylar, Namzaric | $526 | $55,083103 claims |
| GSKShingrix, Breo Ellipta, Trelegy Ellipta | $149 | $41,455118 claims |
| Astellas Pharma US IncMyrbetriq | $314 | $35,67395 claims |
| Johnson & JohnsonXarelto | $124 | $34,65060 claims |
| AmgenProlia | $803 | $19,96411 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $64 | $14,96914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Pocahontas
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
- Glenn GibbonsFort Smith$179K
- Christopher BrownJonesboro$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.